Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.

[1]  C. Cerletti,et al.  Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. , 2003, Trends in pharmacological sciences.

[2]  Paolo Gresele,et al.  Platelets in Thrombotic and Nonthrombotic Disorders – Pathophysiology, Pharmacology and Therapeutics , 2003, Leukemia.

[3]  C. Cerletti,et al.  Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function. , 2002, European journal of pharmacology.

[4]  M. Doherty,et al.  Effect of pain reduction on postural sway, proprioception, and quadriceps strength in subjects with knee osteoarthritis , 2002, Annals of the rheumatic diseases.

[5]  S. Laufer,et al.  Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with COX/5-LOX inhibitory activity , 2002, Inflammation Research.

[6]  Nina Singh,et al.  Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[7]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[8]  R. Sperling,et al.  Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib , 2001, Circulation.

[9]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[10]  S. Laufer,et al.  The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase , 2001, InflammoPharmacology.

[11]  R. Ross,et al.  Atherosclerosis is an Inflammatory Disease , 1998 .

[12]  S. Laufer,et al.  The effects of ML 3000 on antigen-induced responses in sheep. , 1997, Pulmonary pharmacology & therapeutics.

[13]  M. Rawlins,et al.  Prophylactic aspirin and risk of peptic ulcer bleeding , 1995, BMJ.

[14]  J. Wallace,et al.  ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. , 1994, European journal of pharmacology.

[15]  S. Laufer,et al.  Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl- 2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat. , 1994, Arzneimittel-Forschung.

[16]  A. Hatzelmann,et al.  Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. , 1993, Biochemical pharmacology.

[17]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[18]  C. Cerletti,et al.  Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin. , 1986, The New England journal of medicine.

[19]  C. Patrono,et al.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.

[20]  G. Minno,et al.  Prostaglandins as Inhibitors of Human Platelet Aggregation , 1979, British journal of haematology.

[21]  S. Laufer,et al.  Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. , 1995, Arzneimittel-Forschung.